EGFR/ERBB2 was introduced in this study, and therapies targeting EGFR (such as erlotinib, an FDA-approved drug used for advanced pancreatic cancer) are among the most effective treatments for PDAC [108, 109]. Here, EGFR is linked to pancreatic neoplasm.